These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 24797422)
1. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. Spertini F; Perrin Y; Audran R; Pellaton C; Boudousquié C; Barbier N; Thierry AC; Charlon V; Reymond C J Allergy Clin Immunol; 2014 Jul; 134(1):239-240.e13. PubMed ID: 24797422 [No Abstract] [Full Text] [Related]
2. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329 [TBL] [Abstract][Full Text] [Related]
3. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients. Pfaar O; Sager A; Robinson DS Pediatr Allergy Immunol; 2015 May; 26(3):280-286. PubMed ID: 25640879 [TBL] [Abstract][Full Text] [Related]
5. [Comparative study of the effectiveness of 2 methods of specific immunotherapy of pollinoses]. Polsacheva OV; Gushchin IS; Poroshina IuA; Chitaeva VG; Shustova VI Ter Arkh; 1986; 58(4):120-3. PubMed ID: 2424113 [No Abstract] [Full Text] [Related]
6. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Lambert N; Guiddir T; Amat F; Just J Pediatr Allergy Immunol; 2014 Dec; 25(8):829-32. PubMed ID: 25387446 [No Abstract] [Full Text] [Related]
7. Allergen-specific immunotherapy for patients with atopic dermatitis sensitized to animal dander. Chu H; Park KH; Kim SM; Lee JH; Park JW; Lee KH; Park CO Immun Inflamm Dis; 2020 Jun; 8(2):165-169. PubMed ID: 32162849 [TBL] [Abstract][Full Text] [Related]
8. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Didier A; Malling HJ; Worm M; Horak F; Jäger S; Montagut A; André C; de Beaumont O; Melac M J Allergy Clin Immunol; 2007 Dec; 120(6):1338-45. PubMed ID: 17935764 [TBL] [Abstract][Full Text] [Related]
9. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Pfaar O; van Twuijver E; Hecker H; Boot JD; van Ree R; Klimek L Int Arch Allergy Immunol; 2013; 160(4):420-4. PubMed ID: 23183541 [TBL] [Abstract][Full Text] [Related]
10. High-dose sublingual immunotherapy in children at 8-year follow-up. Leonardi S; Spicuzza L; La Rosa M Ann Allergy Asthma Immunol; 2009 Mar; 102(3):259-60. PubMed ID: 19354077 [No Abstract] [Full Text] [Related]
11. Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects. Lombardi V; Beuraud C; Neukirch C; Moussu H; Morizur L; Horiot S; Luce S; Wambre E; Linsley P; Chollet-Martin S; Baron-Bodo V; Aubier M; Moingeon P J Allergy Clin Immunol; 2016 Jul; 138(1):305-308. PubMed ID: 26949057 [No Abstract] [Full Text] [Related]
12. Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis. Bożek A; Kołodziejczyk K; Jarząb J Ann Allergy Asthma Immunol; 2018 Jan; 120(1):53-58. PubMed ID: 29273130 [TBL] [Abstract][Full Text] [Related]
13. New administration routes in immunotherapy. Muñoz-López F Allergol Immunopathol (Madr); 2000; 28(6):295-300. PubMed ID: 11269895 [No Abstract] [Full Text] [Related]